– USA, MA – Cardurion Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Emma Reeve to its Board as an Independent Director, bringing more than 25 years of global financial leadership and board experience across pharmaceutical, medical device, and biopharma companies.
Ms. Reeve will also join the Audit Committee as Chair.
About Emma Reeve
Most recently, Emma Reeve served as CFO of Constellation Pharmaceuticals, Inc., a development-stage oncology company, where she led a 2018 public offering and oversaw the company’s 2021 sale to MorphoSys AG for $1.7 billion. Before Constellation, she acted as interim CFO of Parexel International, a global biopharmaceutical services company, where she was responsible for all aspects of finance and investor relations and helped lead a $5 billion take-private transaction by Pamplona Capital Management. Earlier in her career, she served as CFO of both Inotek Pharmaceuticals and Aton Pharma and held senior finance roles in major pharmaceutical companies, including Novartis, Merck, and Bristol Myers Squibb.
Ms. Reeve currently serves as board chair at Editas Medicine and as a board director at PTC Therapeutics, Aadi Bioscience, and Ribon Therapeutics. She is also a member of the board of Trustees of Tufts Medical Center. Ms. Reeve holds a B.Sc. in computer science from Imperial College, University of London, and is an associate of the Institute of Chartered Accountants in England & Wales.
About Cardurion Pharmaceuticals
Cardurion is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases. Cardurion was founded by physician-scientists with world-class expertise in cardiovascular signaling pathways, and a shared passion to find and develop a pipeline of novel treatment options to improve the lives of patients. Cardurion has two groundbreaking clinical programs in development, a PDE9 program targeting heart failure and the first-ever CaMKII inhibitor in clinical development targeting multiple cardiovascular indications.
For more information: https://cardurion.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.